510(k) device
PSLT with PASCAL Synthesis, PSLT with PASCAL Synthesis TwinStar
Topcon Medical Laser Systems, Inc. · Laser, Ophthalmic (HQF, Class II) · First FDA decision Nov 27, 2017, newest May 25, 2018GlaucomaMacular degeneration and retinal disease
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
510(k) pathway
Device trials
1
Naming "PSLT"
MAUDE reports
0
Brand "PSLT", since 2015
PubMed studies
120
Mentioning "PSLT"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing PSLT with PASCAL Synthesis, PSLT with PASCAL Synthesis TwinStar
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
K180402 · Decided May 25, 2018 · 100 days after receipt
Device type: Laser, Ophthalmic (HQF) · Ophthalmology
K171488 · Decided Nov 27, 2017 · 189 days after receipt
Device type: Laser, Ophthalmic (HQF) · Ophthalmology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "PSLT", any status and sponsor, newest update first.
Alexandria UniversityAcademic, hospital or other
NCT06956313 · 20 participants · Start Feb 1, 2022 · Primary completion Oct 1, 2024
Device: Hydraulic Pressure Lifting Technique; Piezo-Surgical Lifting Technique · For: Sinus Lifting; Piezoelectric Technique
Sites: Alexandria, Egypt
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "PSLT", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code HQF
1,026 reports: 790 malfunction, 231 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "PSLT"[tiab]. The summary above synthesizes these.
- Integration of the pSLT Plasmid into the Salmonella Chromosome Results in a Temperature-Sensitive Growth Defect Due to Aberrant DNA Replication.
Wozniak CE, Hendriksen JJ, Olivera BM, et al. · J Bacteriol · 2020Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Microbe Profile: Salmonella Typhimurium: the master of the art of adaptation.
Perez-Sepulveda BM, Hinton JCD · Microbiology (Reading) · 2025Review, Research Support, Non-U.S. Gov't
- Mating pair stabilization mediates bacterial conjugation species specificity.
Low WW, Wong JLC, Beltran LC, et al. · Nat Microbiol · 2022Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Salmonella pSLT-encoded effector SpvB promotes RIPK3-dependent necroptosis in intestinal epithelial cells.
Dong K, Zhu Y, Deng Q, et al. · Cell Death Discov · 2022
- Salmonella enterica serovar Typhimurium skills to succeed in the host: virulence and regulation.
Fàbrega A, Vila J · Clin Microbiol Rev · 2013Research Support, Non-U.S. Gov't, Review
- PSLT: A Light-Weight Vision Transformer With Ladder Self-Attention and Progressive Shift.
Wu G, Zheng WS, Lu Y, et al. · IEEE Trans Pattern Anal Mach Intell · 2023
- Stabilization of the Virulence Plasmid pSLT of Salmonella Typhimurium by Three Maintenance Systems and Its Evaluation by Using a New Stability Test.
Lobato-Márquez D, Molina-García L, Moreno-Córdoba I, et al. · Front Mol Biosci · 2016
- Expert workshop on the hazards and risks of poorly soluble low toxicity particles.
Driscoll KE, Borm PJA · Inhal Toxicol · 2020Research Support, Non-U.S. Gov't, Review
- Efficacy and safety of selective laser trabeculoplasty and pattern scanning laser trabeculoplasty: a randomised clinical trial.
Wong MOM, Lai IS, Chan PP, et al. · Br J Ophthalmol · 2021Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Outcomes of pattern scanning laser trabeculoplasty and selective laser trabeculoplasty: Results from the lausanne laser trabeculoplasty registry.
Elahi S, Rao HL, Paillard A, et al. · Acta Ophthalmol · 2021
- Carcinogenicity of Poorly Soluble Low Toxicity Particles: Commentary on Epidemiology as a Risk Assessment "Reality Check".
Mundt KA, Santamaria AB, Thompson WJ, et al. · Front Public Health · 2022Review
- The Effectiveness of Pattern Scanning Laser Trabeculoplasty as an Additional Treatment for the Patients of Open-Angle Glaucoma Receiving Full Ocular Hypotensive Medications.
Ueno Y, Haruna Y, Tomita M, et al. · J Clin Med · 2024
Other devices of this type
Also filed under product code HQF.
- Hyperion Ltk SystemSunrise Technologies, Inc. · PMA 2002
- Sunrise Technologies Hyperion(Tm) Holmium Laser System for Laser Thermal Keratoplasty (Ltk)Sunrise Technologies, Inc. · PMA 2001
- Navilas Laser System 577sl (156691)Od-Os GmbH · 510(k) 2025
- VISULAS greenCarl Zeiss Meditec · 510(k) 2023
- Iridex 810 LaserIridex Corporation · 510(k) 2022
- Ophthalmic Yag Laser System YC-200Nidek Co., Ltd. · 510(k) 2020
- LightLas Multi-Wavelength Medical Laser SystemLightmed Corporation · 510(k) 2016
- Lightlas Family of Multi-Wavelength Medical Laser SystemLightmed Corp. · 510(k) 2013
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.